Literature DB >> 33539601

In Regard to "A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08)".

Angela Dalia Ricci1, Alessandro Rizzo1, Giovanni Brandi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33539601      PMCID： PMC8100537          DOI： 10.1002/onco.13703

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  5 in total

1.  Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Authors:  Apinya Jusakul; Ioana Cutcutache; Chern Han Yong; Jing Quan Lim; Mi Ni Huang; Nisha Padmanabhan; Vishwa Nellore; Sarinya Kongpetch; Alvin Wei Tian Ng; Ley Moy Ng; Su Pin Choo; Swe Swe Myint; Raynoo Thanan; Sanjanaa Nagarajan; Weng Khong Lim; Cedric Chuan Young Ng; Arnoud Boot; Mo Liu; Choon Kiat Ong; Vikneswari Rajasegaran; Stefanus Lie; Alvin Soon Tiong Lim; Tse Hui Lim; Jing Tan; Jia Liang Loh; John R McPherson; Narong Khuntikeo; Vajaraphongsa Bhudhisawasdi; Puangrat Yongvanit; Sopit Wongkham; Yasushi Totoki; Hiromi Nakamura; Yasuhito Arai; Satoshi Yamasaki; Pierce Kah-Hoe Chow; Alexander Yaw Fui Chung; London Lucien Peng Jin Ooi; Kiat Hon Lim; Simona Dima; Dan G Duda; Irinel Popescu; Philippe Broet; Sen-Yung Hsieh; Ming-Chin Yu; Aldo Scarpa; Jiaming Lai; Di-Xian Luo; André Lopes Carvalho; André Luiz Vettore; Hyungjin Rhee; Young Nyun Park; Ludmil B Alexandrov; Raluca Gordân; Steven G Rozen; Tatsuhiro Shibata; Chawalit Pairojkul; Bin Tean Teh; Patrick Tan
Journal:  Cancer Discov       Date:  2017-06-30       Impact factor: 39.397

2.  Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

Authors:  Juan Valle; Harpreet Wasan; Daniel H Palmer; David Cunningham; Alan Anthoney; Anthony Maraveyas; Srinivasan Madhusudan; Tim Iveson; Sharon Hughes; Stephen P Pereira; Michael Roughton; John Bridgewater
Journal:  N Engl J Med       Date:  2010-04-08       Impact factor: 91.245

Review 3.  New Horizons for Precision Medicine in Biliary Tract Cancers.

Authors:  Juan W Valle; Angela Lamarca; Lipika Goyal; Jorge Barriuso; Andrew X Zhu
Journal:  Cancer Discov       Date:  2017-08-17       Impact factor: 39.397

4.  A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).

Authors:  Mairéad G McNamara; John Bridgewater; Daniel H Palmer; Olusola Faluyi; Harpreet Wasan; Alkesh Patel; William D Ryder; Safia Barber; Chathunissa Gnanaranjan; Essam Ghazaly; T R Jeff Evans; Juan W Valle
Journal:  Oncologist       Date:  2020-12-03

5.  NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121).

Authors:  Mairéad Geraldine McNamara; Lipika Goyal; Mark Doherty; Christoph Springfeld; David Cosgrove; Katrin Marie Sjoquist; Joon Oh Park; Helena Verdaguer; Chiara Braconi; Paul J Ross; Aimery De Gramont; John Raymond Zalcberg; Daniel H Palmer; Juan W Valle; Jennifer J Knox
Journal:  Future Oncol       Date:  2020-05-06       Impact factor: 3.404
  5 in total
  2 in total

1.  In Reply.

Authors:  Mairéad Geraldine McNamara; Juan W Valle
Journal:  Oncologist       Date:  2021-02-15

Review 2.  Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors.

Authors:  Alessandro Rizzo
Journal:  Medicina (Kaunas)       Date:  2021-05-08       Impact factor: 2.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.